Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label comparative, multicentric study to assess the efficacy and safety of fixed dose combination capsules of Omeprazole and Cinitapride ER in comparison with Omeprazole capsules in patients suffering from non-ulcer dyspepsia (NUD) or gastroesophageal reflux disease (GERD).

Trial Profile

An open label comparative, multicentric study to assess the efficacy and safety of fixed dose combination capsules of Omeprazole and Cinitapride ER in comparison with Omeprazole capsules in patients suffering from non-ulcer dyspepsia (NUD) or gastroesophageal reflux disease (GERD).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cinitapride/omeprazole (Primary) ; Omeprazole
  • Indications Gastro-oesophageal reflux; Non-ulcer dyspepsia
  • Focus Therapeutic Use

Most Recent Events

  • 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by Clinical Trials Registry - India
  • 08 Feb 2010 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top